No change on serum neurofilament light chain concentrations in patients with multiple sclerosis switching from 4 to 6 weeks interval between natalizumab infusions

被引：0
|
作者：
Johnsson, M. [1 ]
Farman, H. [1 ]
Lycke, J. [1 ]
Novakova, L. [1 ]
Malmestrom, C. [1 ]
Zetterberg, H. [2 ,3 ,4 ,5 ]
Blennow, K. [2 ,3 ]
Axelsson, M. [1 ]
机构：
[1] Sahlgrens Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden
[2] Sahlgrens Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden
[3] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden
[4] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England
[5] UCL, UK Dementia Res Inst, London, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P936
引用
收藏
页码：764 / 764
页数：1
相关论文
共 50 条
  • [1] Natalizumab Reduces Serum Concentrations of Neurofilament Light Chain in Secondary Progressive Multiple Sclerosis Patients From the Phase 3 ASCEND Study
    Kapoor, Raju
    Sellebjerg, Finn
    Hartung, Hans-Peter
    Arnold, Douglas
    Freedman, Mark S.
    Jeffery, Douglas
    Miller, Aaron
    Edwards, Keith R.
    Singh, Carol M.
    Chang, Ih
    Ren, Zhang
    Sangurdekar, Dipen
    Zhu, Bing
    Mehta, Devangi
    Ho, Pei-Ran
    Campbell, Nolan
    Edwards, Michael
    Fisher, Elizabeth
    Kieseier, Bernd C.
    Rudick, Richard A.
    Plavina, Tatiana
    NEUROLOGY, 2019, 92 (15)
  • [2] No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
    Johnsson, Magnus
    Farman, Helen H.
    Blennow, Kaj
    Zetterberg, Henrik
    Malmestrom, Clas
    Axelsson, Markus
    Lycke, Jan
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (13) : 2070 - 2080
  • [3] Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis
    Bjornevik, Kjetil
    Munger, Kassandra L.
    Cortese, Marianna
    Barro, Christian
    Healy, Brian C.
    Niebuhr, David W.
    Scher, Ann I.
    Kuhle, Jens
    Ascherio, Alberto
    JAMA NEUROLOGY, 2020, 77 (01) : 58 - 64
  • [4] Natalizumab reduced serum levels of neurofilament light chain in secondary progressive multiple sclerosis patients from the phase 3 ASCEND study
    Kapoor, R.
    Sellebjerg, F.
    Hartung, H. -P.
    Arnold, D. L.
    Freedman, M. S.
    Jeffery, D.
    Miller, A.
    Edwards, K. R.
    Singh, C. M.
    Chang, I.
    Ren, Z.
    Sangurdekar, D.
    Zhu, B.
    Sheikh, S.
    Mehta, D.
    Ho, P. -R.
    Campbell, N.
    Edwards, M.
    Fisher, E.
    Kieseier, B. C.
    Rudick, R. A.
    Plavina, T.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 988 - 988
  • [5] The association between serum neurofilament light chain and OCT measures in multiple sclerosis
    Hagemeier, Jesper
    Tavazzi, Eleonora
    Ramanathan, Murali
    Jakimovski, Dejan
    Bergsland, Niels
    Tomic, Davorka
    Kropshofer, Harald
    Leppert, David
    Michalak, Zuzanna
    Dwyer, Michael
    Benedict, Ralph
    Weinstock-Guttman, Bianca
    Kuhle, Jens
    Zivadinov, Robert
    NEUROLOGY, 2019, 92 (15)
  • [6] Serum neurofilament light chain in relapsing multiple sclerosis patients on a ketogenic diet
    Oh, Unsong
    Woolbright, Emma
    Lehner-Gulotta, Diana
    Coleman, Rachael
    Conaway, Mark
    Goldman, Myla D.
    Brenton, J. Nicholas
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 73
  • [7] Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis
    Fox, Robert J.
    Cree, Bruce A. C.
    de Seze, Jerome
    Gold, Ralf
    Hartung, Hans-Peter
    Jeffery, Douglas
    Kappos, Ludwig
    Montalban, Xavier
    Weinstock-Guttman, Bianca
    Singh, Carol M.
    Altincatal, Arman
    Belviso, Nicholas
    Avila, Robin L.
    Ho, Pei-Ran
    Su, Ray
    Engle, Robert
    Sangurdekar, Dipen
    de Moor, Carl
    Fisher, Elizabeth
    Kieseier, Bernd C.
    Rudick, Richard A.
    NEUROLOGY, 2024, 102 (09) : e209357
  • [8] Serum Neurofilament Light (sNfL) Levels in Patients with Relapsing-remitting Multiple Sclerosis (RRMS) Switching from Natalizumab Every-4-week (Q4W) Dosing to Extended Interval Dosing (EID)
    Foley, John
    Xiong, Kuangan
    Hoyt, Tammy
    Singh, Carol
    Riddle, Evan
    de Moor, Carl
    Campbell, Nolan
    Plavina, Tatiana
    NEUROLOGY, 2020, 94 (15)
  • [9] Serum Neurofilament Light Chain and Glial Fibrillary Acid Protein in Patients With Multiple Sclerosis
    Ayrignac, Xavier
    Maceski, Aleksandra Maleska
    Carra-Dalliere, Clarisse
    Charif, Mahmoud
    Catteau, Cyndi
    Ginestet, Nelly
    Prin, Pauline
    Corti, Lucas
    Pinna, Frederic
    Lehmann, Sylvain
    Labauge, Pierre
    NEUROLOGY, 2019, 92 (15)
  • [10] Renal function influences serum neurofilament light chain levels in patients with multiple sclerosis
    Gasque Rubio, R.
    Cubas Nunez, L.
    Castillo Villalba, J.
    Carratala Bosca, S.
    Alcala, C.
    Perez Miralles, F.
    Quintanilla Bordas, C.
    Laiz Marro, B.
    Casanova Estruch, B.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 585 - 585
12345